Similar articles for PMID: 20682976

Year	Number of Results
2005	1
2006	2
2007	4
2008	7
2009	5
2010	13
2011	5
2012	3
2013	5
2014	6
2015	4
2016	2
2017	3
2019	2
2021	0

1

Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.

Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, Oyama T. Uramoto H, et al. Anticancer Res. 2010 Jul;30(7):2513-7. Anticancer Res. 2010. PMID: 20682976

2

Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.

Uramoto H, Shimokawa H, Hanagiri T, Kuwano M, Ono M. Uramoto H, et al. Lung Cancer. 2011 Sep;73(3):361-5. doi: 10.1016/j.lungcan.2011.01.008. Epub 2011 Feb 18. Lung Cancer. 2011. PMID: 21315472

3

Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.

Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F. Uramoto H, et al. Anticancer Res. 2012 Sep;32(9):3785-90. Anticancer Res. 2012. PMID: 22993320

4

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.

Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T. Suda K, et al. J Thorac Oncol. 2011 Jul;6(7):1152-61. doi: 10.1097/JTO.0b013e318216ee52. J Thorac Oncol. 2011. PMID: 21597390 Free article.

5

Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.

Zhao BX, Wang J, Song B, Wei H, Lv WP, Tian LM, Li M, Lv S. Zhao BX, et al. Mol Med Rep. 2015 Apr;11(4):2767-74. doi: 10.3892/mmr.2014.3058. Epub 2014 Dec 8. Mol Med Rep. 2015. PMID: 25483995

6

Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.

Balko JM, Potti A, Saunders C, Stromberg A, Haura EB, Black EP. Balko JM, et al. BMC Genomics. 2006 Nov 10;7:289. doi: 10.1186/1471-2164-7-289. BMC Genomics. 2006. PMID: 17096850 Free PMC article.

7

[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].

Sun LN, Luan HL, Zang FL, Wang M, Dong N, Guo Y, Sun BC, Zhan ZL. Sun LN, et al. Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):667-70. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 21122380 Chinese.

8

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.

Ji W, Choi CM, Rho JK, Jang SJ, Park YS, Chun SM, Kim WS, Lee JS, Kim SW, Lee DH, Lee JC. Ji W, et al. BMC Cancer. 2013 Dec 27;13:606. doi: 10.1186/1471-2407-13-606. BMC Cancer. 2013. PMID: 24369725 Free PMC article.

9

Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.

Xie M, He CS, Wei SH, Zhang L. Xie M, et al. Eur J Cancer. 2013 Nov;49(16):3559-72. doi: 10.1016/j.ejca.2013.07.007. Epub 2013 Aug 2. Eur J Cancer. 2013. PMID: 23916913

10

De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.

Takeda M, Okamoto I, Fujita Y, Arao T, Ito H, Fukuoka M, Nishio K, Nakagawa K. Takeda M, et al. J Thorac Oncol. 2010 Mar;5(3):399-400. doi: 10.1097/JTO.0b013e3181cee47e. J Thorac Oncol. 2010. PMID: 20186026 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed